Related Experiment Videos
[Clinically diagnosed corticobasal degeneration (CBD)]
1Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital.
Rinsho Shinkeigaku = Clinical Neurology
|January 1, 1993
Summary
This study presents a case of corticobasal degeneration (CBD) with dementia, highlighting unique brain imaging findings. Early-stage CBD may show unilateral hypoperfusion and hypometabolism in the basal ganglia and thalamus.
Area of Science:
- Neuroscience
- Neurology
- Radiology
Background:
- Corticobasal degeneration (CBD) is a rare neurodegenerative disorder.
- Distinguishing CBD from atypical Alzheimer's disease (AD) can be challenging.
- Early diagnosis is crucial for patient management and research.
Observation:
- A 67-year-old male presented with apraxia, amnesia, and right-sided muscle rigidity.
- Neurological examination revealed dysarthria, dysphagia, dystonia, hyperreflexia, and ataxic gait.
- Brain MRI and CT showed significant left parieto-occipital atrophy.
Findings:
- 123I-IMP-SPECT and 18F-FDG-PET suggested degenerative atrophy.
- FDG-PET revealed decreased cerebral blood flow and glucose metabolism in the left cerebral cortex, basal ganglia, and thalamus.
- Unilateral hypoperfusion and hypometabolism in the basal ganglia and thalamus were observed.
Implications:
- These findings suggest that unilateral basal ganglia and thalamus hypoperfusion/hypometabolism may characterize early-stage CBD.
- This case contributes to understanding the neuroimaging features of atypical neurodegenerative diseases.
- Further research is needed to validate these imaging biomarkers for early CBD detection.